CSF3 and cancer: The two study cohorts were comparable with regard to disease severity, previous cancer treatments, clinical status at chemotherapy initiation and prescribed chemotherapy regimens, but patients who received a daily G-CSF were older and completed a higher number of chemotherapy cycles, which suggests a higher risk for neutropenia in this subgroup.